RK‐287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model
Open Access
- 20 September 2018
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 109 (12) , 4003-4014
Abstract
Aberrant activation of Wnt/β‐catenin signaling causes tumorigenesis and promotes the proliferation of colorectal cancer cells. Porcupine inhibitors, which block secretion of Wnt ligands, may have only limited clinical impact for the treatment of colorectal cancer, because most colorectal cancer is caused by loss‐of‐function mutations of the tumor suppressor adenomatous polyposis coli (APC) downstream of Wnt ligands. Tankyrase poly(ADP‐ribosyl)ates (PARylates) Axin, a negative regulator of β‐catenin. This post‐translational modification causes ubiquitin‐dependent degradation of Axin, resulting in β‐catenin accumulation. Tankyrase inhibitors downregulate β‐catenin and suppress the growth of APC‐mutated colorectal cancer cells. Herein, we report a novel tankyrase‐specific inhibitor RK‐287107, which inhibits tankyrase‐1 and ‐2 four‐ and eight‐fold more potently, respectively, than G007‐LK, a tankyrase inhibitor that has been previously reported as effective in mouse xenograft models. RK‐287107 causes Axin2 accumulation and downregulates β‐catenin, T‐cell factor/lymphoid enhancer factor reporter activity and the target gene expression in colorectal cancer cells harboring the shortly truncated APC mutations. Consistently, RK‐287107 inhibits the growth of APC‐mutated (β‐catenin‐dependent) colorectal cancer COLO‐320DM and SW403 cells but not the APC‐wild (β‐catenin‐independent) colorectal cancer RKO cells. Intraperitoneal or oral administration of RK‐287107 suppresses COLO‐320DM tumor growth in NOD‐SCID mice. Rates of tumor growth inhibition showed good correlation with the behavior of pharmacodynamic biomarkers, such as Axin2 accumulation and MYC downregulation. These observations indicate that RK‐287107 exerts a proof‐of‐concept antitumor effect, and thus may have potential for tankyrase‐directed molecular cancer therapy.Keywords
Funding Information
- Japan Agency for Medical Research and Development (15cm0106030h0005, 16cm0106102h0001, 17cm0106102h0002, 18cm0106102h0003, G2011‐011, JP17am0101086, M15114)
- Princess Takamatsu Cancer Research Fund
- Japan Society for the Promotion of Science (16H04716, 17K07186)
This publication has 34 references indexed in Scilit:
- Identification of NVP-TNKS656: The Use of Structure–Efficiency Relationships To Generate a Highly Potent, Selective, and Orally Active Tankyrase InhibitorJournal of Medicinal Chemistry, 2013
- WIKI4, a Novel Inhibitor of Tankyrase and Wnt/ß-Catenin SignalingPLOS ONE, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Ubiquitin Ligase RNF146 Regulates Tankyrase and Axin to Promote Wnt SignalingPLOS ONE, 2011
- A novel yeast cell-based screen identifies flavone as a tankyrase inhibitorBiochemical and Biophysical Research Communications, 2010
- Tankyrase inhibition stabilizes axin and antagonizes Wnt signallingNature, 2009
- Structure–activity relationship studies of small-molecule inhibitors of Wnt responseBioorganic & Medicinal Chemistry Letters, 2009
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 2008
- Tankyrase 1 and Tankyrase 2 Are Essential but Redundant for Mouse Embryonic DevelopmentPLOS ONE, 2008
- Functional Subdomain in the Ankyrin Domain of Tankyrase 1 Required for Poly(ADP-Ribosyl)ation of TRF1 and Telomere ElongationMolecular and Cellular Biology, 2004